News & Events
![](https://www.forxtherapeutics.com/wp-content/uploads/2020/01/border-bottom-card.png)
FoRx Therapeutics Announces Development Candidate Nomination of Potential Best-in-Class PARG Inhibitor FORX-428
Basel, Switzerland, 01 June, 2020 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Ulrich Lücking, PhD, as Head of Chemistry.
FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer
Basel, Switzerland, 01 June, 2020 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Ulrich Lücking, PhD, as Head of Chemistry.
FoRx Therapeutics AG appoints Ulrich Lücking as Head of Chemistry
Basel, Switzerland, 01 June, 2020 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Ulrich Lücking, PhD, as Head of Chemistry.
FoRx Therapeutics AG Raises EUR 10 Million Seed Round
First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer
Basel, Switzerland, 22 April, 2020 – FoRx Therapeutics AG (FoRx), the biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways, today announced the closing of a EUR 10 million seed financing led by M Ventures (venture capital arm of Merck), Novartis Venture Fund and Omega Funds. Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE) and LSP (Life Sciences Partners) also joined the seed financing. The company also announces the appointment of Colin Goddard as Executive Chairman.